Precision BioSciences
302 East Pettigrew St.
Durham
North Carolina
27701
United States
Tel: 919-314-5512
Fax: 480-393-5553
Website: https://precisionbiosciences.com/
About Precision BioSciences
Precision BioSciences is dedicated to improving life through its proprietary genome editing platform, “ARCUS.” Precision BioSciences leverages ARCUS in the development of its product candidates which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision BioSciences is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food.
74 articles with Precision BioSciences
-
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
-
Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States
7/18/2019
Research Triangle Park Facility to Manufacture Precision’s Pipeline of Off-the-Shelf CAR T Product Candidates to Support Clinical Trials
-
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
-
Durham, NC-based Precision BioSciences set its initial public offering (IPO) price at $16 per share, raising $126.4 million. It began trading today on the Nasdaq under the ticker symbol DTIL.
-
A summary of IPOs from companies in the biotech and pharma world since March 1, 2019.
-
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.
-
BioSpace Movers and Shakers: March 15
3/15/2019
Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more. -
Raymond Schinazi Joins Precision BioSciences Board of Directors
3/14/2019
Globally recognized leader in antiviral drug discovery and development
-
Precision BioSciences Enters Into Private Convertible Note Financing
3/11/2019
Precision BioSciences announced that it has entered into an agreement for the issuance and sale of convertible promissory notes in a private placement transaction in the aggregate principal amount of approximately $40 million, which will bring the Company’s total capital generated in the last year to over $150 million and total funding since inception to over $300 million.
-
Durham, NC-based Precision BioSciences filed on Friday with the U.S. Securities Exchange Commission for an initial public offering (IPO). The company, which focuses on gene-edited CAR-T cell therapies for cancer, plans to raise $100 million.
-
Precision BioSciences Announces Formation of Scientific Advisory Board with Anderson, Kantarjian, Schinazi and Turtle
1/16/2019
Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, M.D., Hagop Kantarjian, M.D., Raymond Schinazi, Ph.D., D.Sc. and Cameron Turtle, MBBS, Ph.D.
-
Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors
12/20/2018
Sharp brings a wealth of experience in financial management and corporate strategy in rare disease, gene therapy and oncology.
-
Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space
12/6/2018
SpaceX Falcon 9 Delivering ARCUS Gene Editing to the International Space Station
-
Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
11/27/2018
Precision BioSciences and Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR0191, an allogeneic anti-CD19 CAR T therapy for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
-
Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement
11/14/2018
Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS® genome-editing technology
-
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
-
Elo Life Systems Launches Australian Subsidiary in Queensland
11/5/2018
Elo Life Systems has opened a new Australian location at the Queensland University of Technology (QUT), Gardens Point Campus in Brisbane.
-
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
9/12/2018
Gilead Sciences and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.
-
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
-
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”